Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Enliven Therapeutics, Inc.NASDAQ: ELVN
EPS (Basic) · Q3 FY2026 · quarter ended Sep 2026
EPS (Basic) remains negative
Q3 FY2026 EPS (Basic) was -$0.36, compared with -$0.32 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.68.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -$1.77 (+3.0%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.36+26.5% QoQ
- Last fiscal yearDec 2025
- -$1.83+3.2% YoY
- LTMSep 2026
- -$1.68+8.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.5% | -12.7% | -0.2 pp |
| 1 year | +3.2% | +3.0% | -0.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.83) USD
- Year-over-year change
- +3.2%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.83) | +3.2% |
| FY2024 | 2024-12-31 | (1.89) | +6.0% |
| FY2023 | 2023-12-31 | (2.01) | +66.7% |
| FY2022 | 2022-12-31 | (6.03) | -90.2% |
| FY2021 | 2021-12-31 | (3.17) | — |
EPS (Basic) vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 EPS (Basic) of -$1.68 is the 6th highest of the 11 companies compared; the peer median is -$1.87.
- Its year-over-year change of +8.7% is the 7th highest of 11, against a peer median of +21.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $8.13 | +80.7% | +62.7% | |
| LTM Jul 2026 | $3.29 | +53.7% | +71.6% | |
| LTM Jun 2026 | -$0.43 | +31.0% | — | |
| LTM Mar 2026 | -$1.44 | +23.0% | — | |
| LTM Jun 2026 | -$1.57 | +19.5% | — | |
| LTM Sep 2026 | -$1.68 | +8.7% | — | |
| LTM Mar 2026 | -$2.18 | -33.7% | — | |
| LTM Mar 2026 | -$2.8 | +27.6% | — | |
| LTM Mar 2026 | -$3.53 | +6.4% | — | |
| LTM Mar 2026 | -$3.75 | -21.4% | — | |
| LTM Jun 2026 | -$8.86 | -96.5% | — | |
| Peer median (excluding ELVN) | -$1.87 | +21.2% | +67.1% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 263K |
| Gross Profit | 0 | 0 | 0 | 0 | (263K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Selling, General & Admin | 4.29M | 7.77M | 18.96M | 23.78M | 33.8M |
| Operating Expenses | 24.76M | 38.79M | 83.53M | 104.55M | 119.4M |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| EBITDA | (24.63M) | (37.45M) | (71.29M) | (88.48M) | (103.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (24.76M) | (38.79M) | (83.53M) | (104.55M) | (119.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Income Before Tax | (24.74M) | (37.66M) | (71.58M) | (88.79M) | (103.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 232K | 0 |
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| EPS (Diluted) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| Weighted Avg Shares | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M |
| Weighted Avg Shares (Diluted) | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.